
Please try another search
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The company’s lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), for the treatment of non-small and small cell lung cancer. It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreatic duct; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has license agreement from the University of Pittsburgh of the Commonwealth System of Higher Education (University of Pittsburgh) multiple technologies relating to the development of a gene therapy product for both Type 1 and Type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Name | Age | Since | Title |
---|---|---|---|
Shu Kam Mok | 65 | - | Member of Scientific & Medical Advisory Board |
Pasi Antero Janne | - | - | Member of Scientific & Medical Advisory Board |
George Simon | - | - | Member of Scientific & Medical Advisory Board |
Ryan M. Confer | 43 | 2016 | President, CEO, CFO & Director |
Jack A. Roth | - | - | Chairman of Scientific & Medical Advisory Board |
Michael Morse | - | 2021 | Member of Clinical Advisory Board |
Jose Antonio Moreno Toscano | 52 | 2020 | Independent Non-Executive Chairman |
Brent M. Longnecker | 69 | 2020 | Independent Director |
George K. Gittes | - | 2020 | Member of Scientific Advisory Board |
James E. Rothman | 74 | 2012 | Strategic Advisor to the Board of Directors |
William R. Wilson | 75 | 2020 | Independent Director |
George E. Peoples | 62 | 2021 | Member of Clinical Advisory Board |
Andrew B. Becker | - | 2021 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review